New PET scan could spot hidden prostate cancer after treatment

NCT ID NCT07185165

Recruiting now Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether a special PET/CT scan using flotufolastat F 18 can accurately find prostate cancer that remains or returns after focal therapy (such as laser or freezing). The study will enroll 81 men who had focal therapy 6 to 36 months ago. If the scan works well, it may offer a less invasive way to check for leftover cancer compared to standard methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flotufolastat F 18 (radioactive tracer)
What this could lead to: If successful, this imaging method could offer a less invasive way to find residual or recurrent prostate cancer after focal therapy, potentially guiding better treatment decisions.
What could go wrong: This is a small, early-phase trial (81 participants) focused on imaging accuracy, not treatment. The method may not be reliable enough to replace standard biopsies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.